<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR341.html">Part 341
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 341.85  Labeling of permitted combinations of active ingredients.
                            </h3>
                            <p class="depth0">The statements of identity, indications, warnings, and directions  for use, respectively, applicable to each ingredient in the product may  be combined to eliminate duplicative words or phrases so that the  resulting information is clear and understandable.</p><p class="depth1"><em>(a)</em>.</p><p class="depth2"><em>(1)</em> For permitted combinations identified in Sec. 341.40(a), (c),  (f), (g), (l), (m), (n), (o), (q), and (r) containing an analgesic- antipyretic active ingredient. The analgesic-antipyretic component of  the product shall be identified as a ``pain reliever'' or ``analgesic  (pain reliever).'' If the product is also labeled to relieve fever, then  the analgesic-antipyretic component is identified as a ``pain reliever- fever reducer'' or ``analgesic (pain reliever)-antipyretic (fever  reducer).''</p><p class="depth2"><em>(2)</em> [Reserved]</p><p class="depth1"><em>(b)</em>, may  also be used, as provided in Sec. 330.1(c)(2) of this chapter, subject  to the provisions of section 502 of the Federal Food, Drug, and Cosmetic  Act (the act) relating to misbranding and the prohibition in section  301(d) of the act against the introduction or delivery for introduction  into interstate commerce of unapproved new drugs in violation of section  505(a) of the act.</p><p class="depth2"><em>(1)</em> For permitted combinations containing an analgesic-antipyretic  active ingredient identified in Sec. 341.40(a), (c), (f). (g), (l),  (m), (n), (o), (q), and (r) when labeled for relief of general cough- cold symptoms and/or the common cold. </p><p class="depth3"><em>(i)</em> The labeling for the  analgesic-antipyretic ingredients states ``[bullet] temporarily relieves  [bullet] minor aches and pains [bullet] headache'' and ``[bullet]  temporarily reduces fever''.</p><p class="depth3"><em>(ii)</em> The labeling for the cough-cold ingredient(s) may follow a  separate bullet(s) or may be combined with the relieves part of the  indication in paragraph (b)(1)(i) of this section.</p><p class="depth2"><em>(2)</em> For permitted combinations containing an analgesic-antipyretic  active ingredient identified in Sec. 341.40(a), (c), (f), (g), (m),  (q), and (r) when labeled for relief of hay fever/allergic rhinitis and/ or nasal congestion symptoms. </p><p class="depth3"><em>(i)</em> The labeling for the analgesic- antipyretic ingredients states ``[bullet] temporarily relieves [bullet]  minor aches and pains [bullet] headache''.</p><p class="depth3"><em>(ii)</em>, as appropriate, and the  labeling for any other cough-cold combination. This labeling may follow  a separate bullet(s) or may be combined with the indication in paragraph  (b)(2)(i) of this section.</p><p class="depth2"><em>(3)</em> For permitted combinations containing an oral analgesic- antipyretic active ingredient identified in Sec. 341.40(a), (c), (f),  (g), (m), (q), and (r) when labeled for relief of general cough-cold  symptoms and/or the common cold and for relief of hay fever/allergic  rhinitis and/or nasal congestion symptoms. The labeling states both  indications in paragraphs (b)(1) and (b)(2) of this section.</p><p class="depth2"><em>(4)</em> For permitted combinations containing an oral anesthetic- analgesic active ingredient identified in Sec. 341.40(k), (s), (t),  (z), (aa), and (bb). The labeling for   the anesthetic-analgesic ingredients in part 356 of this chapter should  be used.</p><p class="depth2"><em>(5)</em> For permitted combinations containing camphor, menthol, and  eucalyptus oil identified in Sec. 341.40(u). The labeling for  antitussive ingredients in Sec. 341.74(b) should be used.</p><p class="depth2"><em>(6)</em> For permitted combinations containing levmetamfetamine with  aromatics identified in Sec. 341.40(v). The labeling for nasal  decongestant ingredients in Sec. 341.80(b) should be used.</p><p class="depth2"><em>(7)</em> Other allowable statements. In addition to the required  information identified in paragraph (b) of this section, the labeling of  the combination drug product may contain any of the ``other allowable  statements'' (if any), that are identified in the applicable OTC drug  monographs, provided such statements are neither placed in direct  conjunction with information required to appear in the labeling nor  occupy labeling space with greater prominence or conspicuousness than  the required information.</p><p class="depth1"><em>(c)</em> of this section.</p><p class="depth2"><em>(1)</em> For permitted combinations containing an antitussive and an  analgesic-antipyretic identified in Sec. 341.40(f), (g), (l), and (m).  The labeling states the following warnings:</p><p class="depth3"><em>(i)</em> For products labeled only for adults. The following warning  should be used instead of the warnings in Sec. 341.74(c)(1) and part  343 of this chapter: ``Stop use and ask a doctor if [in bold type]  [bullet] pain or cough gets worse or lasts more than 7 days [bullet]  fever gets worse or lasts more than 3 days [bullet] redness or swelling  is present [bullet] new symptoms occur [bullet] cough comes back or  occurs with rash or headache that lasts. These could be signs of a  serious condition.''</p><p class="depth3"><em>(ii)</em> For products labeled only for children under 12 years of age.  The following warning should be used instead of the warnings in Sec.  341.74(c)(3) and part 343 of this chapter: ``Stop use and ask a doctor  if [in bold type] [bullet] pain or cough gets worse or lasts more than 5  days [bullet] fever gets worse or lasts more than 3 days [bullet]  redness or swelling is present [bullet] new symptoms occur [bullet]  cough comes back or occurs with rash or headache that lasts. These could  be signs of a serious condition.''</p><p class="depth3"><em>(iii)</em> For products labeled for both adults and for children under 12  years of age. The following warning should be used instead of the  warnings in Sec. 341.74(c)(2) and part 343 of this chapter: ``Stop use  and ask a doctor if [in bold type] [bullet] pain or cough gets worse or  lasts more than 5 days (children) or 7 days (adults) [bullet] fever gets  worse or lasts more than 3 days [bullet] redness or swelling is present  [bullet] new symptoms occur [bullet] cough comes back or occurs with  rash or headache that lasts. These could be signs of a serious  condition.''</p><p class="depth2"><em>(2)</em> For permitted combinations containing an expectorant and an  analgesic-antipyretic identified in Sec. 341.40(o). The labeling states  the following warnings:</p><p class="depth3"><em>(i)</em> of this section should be used instead of the warnings in  Sec. 341.78(c)(3) and part 343 of this chapter.</p><p class="depth3"><em>(ii)</em> of this section should be used  instead of the warnings in Sec. 341.78(c)(3) and part 343 of this  chapter.</p><p class="depth3"><em>(iii)</em> of this section  should be used instead of the warnings in Sec. 341.78(c)(3) and part  343 of this chapter.</p><p class="depth2"><em>(3)</em> For permitted combinations containing a nasal decongestant and  an analgesic-antipyretic identified in Sec. 341.40(c), (g), (m), (n),  (q), and (r). The labeling states the following warnings:</p><p class="depth3"><em>(i)(B)</em> and  part 343 of this chapter: ``Stop use and ask a doctor if [in bold type]  [bullet] pain or nasal congestion gets worse or lasts more than 7 days  [bullet] fever gets worse or lasts more than 3 days [bullet] redness or  swelling is present [bullet] new symptoms occur''.</p><p class="depth3"><em>(ii)(B)</em> and part 343 of this chapter: ``Stop use and ask a  doctor if [in bold type] [bullet] pain or nasal congestion gets worse or  lasts more than 5 days [bullet] fever gets worse or lasts more than 3  days [bullet] redness or swelling is present [bullet] new symptoms  occur''.</p><p class="depth3"><em>(iii)</em> and part 343 of this chapter: ``Stop  use and ask a doctor if [in bold type] [bullet] pain or nasal congestion  gets worse or lasts more than 5 days (children) or 7 days (adults)  [bullet] fever gets worse or lasts more than 3 days [bullet] redness or  swelling is present [bullet] new symptoms occur''.</p><p class="depth2"><em>(4)</em> For permitted combinations containing an antihistamine combined  with an oral antitussive. The labeling states the warning ``When using  this product [in bold type] [bullet] may cause marked drowsiness.'' The  word ``marked'' may be deleted from the warning upon petition under the  provisions of Sec. 10.30 of this chapter provided adequate data are  submitted to demonstrate that the combination product does not cause a  significant increase in drowsiness as compared with each active  ingredient when tested alone. The petition and the data it contains will  be maintained in a permanent file for public review in the Division of  Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers  Lane, rm. 1061, Rockville, MD 20852.</p><p class="depth2"><em>(5)</em> For permitted combinations containing camphor, menthol, and  eucalyptus oil identified in Sec. 341.40(u). The labeling states the  warnings for topical antitussive ingredients in Sec. 341.74(c).</p><p class="depth2"><em>(6)</em> For permitted combinations containing levmetamfetamine with  aromatics identified in Sec. 341.40(v). The labeling states the  warnings for topical nasal decongestant ingredients in Sec.  341.80(c)(2).</p><p class="depth1"><em>(d)</em>  of this section. When the time intervals or age limitations for  administration of the individual ingredients differ, the directions for  the combination product may not exceed any maximum dosage limits  established for the individual ingredients in the applicable OTC drug  monograph.</p><p class="depth2"><em>(1)</em> For permitted combinations containing an anesthetic/analgesic  and/or a demulcent in a liquid dosage form identified in Sec.  341.40(k), (s), (t), (w), (x), (y), (z), (aa), and (bb). The labeling  states ``[optional, bullet] gargle, swish around, or keep in the mouth  for at least 1 minute and then swallow. Do not spit out.''</p><p class="depth2"><em>(2)</em> For permitted combinations containing camphor, menthol, and  eucalyptus oil identified in Sec. 341.40(u). The labeling states the  directions for topical antitussive ingredients in Sec. 341.74(d).</p><p class="depth2"><em>(3)</em> For permitted combinations containing levmetamfetamine with  aromatics identified in Sec. 341.40(v). The labeling states the  directions for topical nasal decongestant ingredients in Sec.  341.80(d)(2)(i) and (d)(2)(viii).  [67 FR 78170, Dec. 23, 2002, as amended at 70 FR 58977, Oct. 11, 2005;  71 FR 43362, Aug. 1, 2006]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
